# BPC-157 Legal Status, FDA 503A Category, and Compounding Access (BPC-157) > BPC-157 legal status: not FDA-approved, placed in FDA 503A Category 2 in 2023, and named on the July 2026 PCAC agenda under active review. How lawful compounded access works. Cited to FDA. Access is under active FDA review and may expand in 2026 — anchored on what the FDA actually says today. The current category, the scheduled evaluation, and how lawful compounded access works, cited to FDA. ## The forward signal: BPC-157 is under active FDA review The most current development in BPC-157's legal status points forward. BPC-157 — under the entries "BPC-157 (free base)" and "BPC-157 acetate" — is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [18]. The same agenda also lists KPV, TB-500, and MOTs-C [18]. That is real momentum: access to compounded BPC-157 is actively being evaluated, and it may expand depending on how that process unfolds. It is also precisely bounded. A PCAC meeting is a scheduled evaluation and discussion — it is advisory, not a listing decision, not a reclassification, and not a change in BPC-157's current status [18]. Being discussed by PCAC is a step in FDA's evaluation, not the outcome of it [17]. No result of the July 2026 meeting should be assumed, and none is asserted here. This page leads with that forward signal because it is the live part of the story — but everything below it is the present-tense fact the forward signal sits on top of. ## The current fact: FDA 503A Category 2 As of today, BPC-157 is a research peptide that the FDA placed in 503A "Category 2" — bulk substances that may present significant safety risks. The placement took effect with the FDA's September 29, 2023 update to its list of bulk drug substances nominated for use under section 503A [16]. The FDA's stated rationale included concerns about potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [16]. Two consequences follow directly. As a Category 2 substance, BPC-157 is not within the FDA's enforcement-discretion policy for 503A compounding — the policy that applies to Category 1 substances does not cover it, and the FDA has stated it would consider taking action against a compounder using a Category 2 substance [17]. And separately, BPC-157 is not an FDA-approved drug: no New Drug Application or Biologics License Application has approved it as a finished medicine [17]. Drug approval and compounding eligibility are distinct questions, and BPC-157 fails both as of this writing. The July 2026 PCAC discussion does not alter that present status. Until and unless the FDA takes a formal action, Category 2 — effective September 29, 2023 — is the standing fact [16]. ## How 503A and 503B compounding work U.S. drug compounding runs through two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and licensed physicians, made pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight and FDA registration and inspection [17]. A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list [17]. Substances not yet on a bulks list are evaluated through a public nomination process with input from the PCAC [17]. The FDA's earlier interim policy sorted nominated substances into Category 1 (covered by enforcement discretion during evaluation) and Category 2 (identified as raising significant safety risks; not covered) [17]. The eligibility caveat is the operative point for BPC-157: a Category 2 substance is not eligible for routine 503A compounding while that status stands [16]. ## How lawful compounded peptide access works in general In general terms, a legally compounded medication is prepared only after a specific patient is evaluated by a licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription [17]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [17]. Telehealth can serve as the front-end channel for that prescriber evaluation — a route to a licensed-prescriber consultation and prescription — but it does not change which substances are eligible to be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription [17]. The decisive constraint is ingredient eligibility: a compounder may use an active ingredient only if it is permitted under the 503A/503B framework, and a substance the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [16]. For BPC-157 specifically, that flag is its Category 2 placement. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance. BPC-157 is also prohibited in sport at all times by the World Anti-Doping Agency under the S0 non-approved-substances category — a relevant status for any athlete subject to anti-doping rules. --- A neon research console reading the published BPC-157 record — studies logged, citations indexed, and the gaps flagged; not a clinic, not a vendor, not a prescription.